Dipeptidyl-Peptidase IV Inhibitor

Adults with type 2 diabetes who use a GLP-1 receptor agonist for more than 1 year may have an increased risk for thyroid cancer, according to findings published in Diabetes Care.

SGLT2 inhibition in older patients with type 2 diabetes was associated with lower risk for incident atrial fibrillation compared with dipeptidyl peptidase IV inhibition or GLP-1 receptor agonist treatment, researchers reported.

The use of SGLT2 inhibitors with type 2 diabetes is associated with lower risks for end-stage renal disease and acute renal failure compared with DPP-IV inhibitor use, according to study findings from Hong Kong.

Clinicians should be cautious when prescribing certain antihyperglycemic agents for people with type 2 diabetes at risk for fracture, particularly when a patient is older with long disease duration or complications, according to a speaker.

New data from the CORONADO study show that 20% of people with diabetes hospitalized with COVID-19 die within 28 days of admission, whereas half are discharged in that same time span.

Adults with type 2 diabetes who were hospitalized with COVID-19 in northern Italy had a lower mortality rate and better health outcomes when treated with the DPP-IV inhibitor sitagliptin, according to study data published in Diabetes Care.

SGLT2 inhibitor use is associated with an almost threefold increased risk for diabetic ketoacidosis compared with use of DPP-IV inhibitors, according to findings published in Annals of Internal Medicine.

Insulin — not DPP-IV inhibitors or GLP-1 receptor agonists — should be the agent of choice for the management of severely ill patients with diabetes and coronavirus infections; this position is supported by extensive historical experience and the increased adoption of continuous glucose monitoring, according to a literature review published in Endocrine Reviews.

More than half of adults with type 2 diabetes prescribed DPP-IV inhibitor therapy discontinued the medications within 1 year of initiating insulin, according to findings from a U.S. health claims database analysis.

The skin condition bullous pemphigoid may be more likely to develop in adults with type 2 diabetes who use DPP-IV inhibitors vs. those who do not use the medication, especially if they also use spironolactone or have dementia, according to findings published in the Journal of Diabetes and its Complications.